


In re application of: [redacted] oji et al.  
Application No.: 09/830,706  
Page 3 of 3

Respectfully submitted,



---

Peter F. Corless (Reg. No. 33,860)  
Edwards & Angell, LLP  
P.O. Box 9169  
Boston, MA 02209  
(617) 439-4444

Date: January 7, 2002

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION:**

On page 9, lines 26-27:

-- Figure 1 shows alignment of amino acid sequences for TxRII $\alpha$  and the known TxR  
(SEQ ID NOS 2 and 38).--

On page 21, lines 6-9:

-- Figure 1 (SEQ ID NOS 2 and 38) shows the alignment of amino acid sequences for TxRII $\alpha$  of  
the present invention and the known TxR.--

On page 22, line 3:

-- 5' primer (XIAP2486 (32mer)) (SEQ ID NO: 6).--

On page 22, line 9:

-- 3' primer (XIAP 2482 (32 mer)) (SEQ ID NO: 7).--

On page 28, line 36 through to line 4 on page 29:

-- Moreover, functional regions (a redox active center, a FAD-binding ~~biding~~ region, a  
NADPH-binding region, a selenocysteine active center) reported in human thioredoxin reductase  
were completely conserved in the homologous manner in X19 ~~Figure 1, SEQ ID NO: 1/2~~  
(Figure 1).--

On page 29, lines 27-28:

-- TxRII-sF3 5'-TAT GAT CTC CTG GTG GTC-3' (SEQ ID NO: 8)

TxRII-sR2 5'-GTC ATC ACT TGT GAT TCC-3' (SEQ ID NO: 9).--

On page 30, line 36:

-- 5'-ACA GCT TCT GCC ATC TTC CTC-3' (SEQ ID NO: 10).--

On page 31, line 1:

--5'-AGA AGG TTC CAC GTA GTC CAC-3' (SEQ ID NO: 11).--

On page 31, line 3:

-- 5'-CCA TAC GAT GTT CCA GAT TAC-3' (SEQ ID NO: 12).--